A unique approach for discovering new autophagy therapeutics
The Lysoseeker™ Platform
An unbiased, data-driven approach to discover new biology.
Lysoseeker™ is a set of capabilities which goes from screen to drug via new mechanisms and disease utility.
We start with an unbiased phenotypic screen and use proprietary technologies to understand the mechanisms and targets of the autophagy-inducing molecules we identify.
We also screen these new molecules in a variety of translatable cellular models of disease.
With Lysoseeker™ we have discovered several highly promising lead molecules which are being optimised towards the clinic and restore autophagy in vivo via completely novel biology.
The process of autophagy features multiple steps and is highly dynamic.
We are building an understanding of these processes at a transcriptional and proteomic level and probing them with molecules to discover new intervention points, with the goal of boosting the whole process.
Our unbiased approach is leading to numerous opportunities for intervention.
Samsara Therapeutics Receives $3.2 Million Seed Funding for Further Pipeline Expansion.
Our strategy in Samsara is to treat diseases where there is a high unmet need. But we also want to find out how our molecules work to affect healthspan and longevity.
Over the last twenty years or so, the phenomenon of autophagy has become a hot topic in the world of biology.